Sandoz One Source, a patient services centre, was also launched
Zarxio by Sandoz, a Novartis company, is now available in the US. Zarxio is the first biosimilar approved by the US Food and Drug Administration (FDA) and the first to launch in the US.
Richard Francis, Global Head, Sandoz said, “With the launch of Zarxio, we look forward to increasing patient, prescriber and payor access to filgrastim in the US by offering a high-quality, more affordable version of this important oncology medicine.”
“While biologics have had a significant impact on how diseases are treated, their cost and co-pays are difficult for many patients and the healthcare budget in general. Biosimilars can help to fill an unmet need by providing expanded options, greater affordability and increased patient access to life-saving therapies,” said Dr Ralph Boccia, Medical Director of the Center for Cancer and Blood Disorders, and Chief Medical Officer, International Oncology Network (ION).
With the launch of Zarxio, Sandoz also offers Sandoz One Source, a patient services centre, providing support that connects the patient to the information and resources they need.
The launch follows the FDA approval of Zarxio on March 6, 2015.